65,437 trials
Astigmatism
Primary: Assessment of Conjunctival Hyperemia in Subjects That Are High Myopes (Have a High Degree of Nearsightedness) — 1.10; 1.23 Units on a scale
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Advanced Solid Tumors · Neoplasms
Primary: Maximum Plasma Concentration (Cmax) — 338.23; 308.37 nanogram (ng)/millilter(mL)
Carcinoma, Renal Cell
Primary: Pharmacokinetics Measured as Area Under Curve (AUC[0-12h]) — 35.5; 5.7 mg*hour/Liter
Dysmenorrhea
Primary: Number of Participants With Intracyclic Bleeding at Cycle 6 — 40; 4 participants
Attention Deficit Hyperactivity Disorder
Primary: Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted) — 88.0; 116.1 Problems attempted — p=<0.0001
Post Abortion Care
Primary: Contraceptive Acceptability and Use of Contraceptives During the 6-month Follow-up — 121; 86 participants
Smoking Cessation
Primary: Percentage of Participants With 4-week Continuous Abstinence (CA) — 53.9; 19.4 Percentage of participants — p=<0.0001
Lymphoma, Non-Hodgkin
Primary: Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis — 0.593; 0.196; 0.407; 0.804 proportion of participants
Generalized Anxiety Disorder
Primary: Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings — 4; 6; 7 Participants
Alcohol Dependence
Primary: "Drinking Days" in the Previous Month — 19.54; 15.18; 17.75; 22.11 Days — p=<0.001
Major Depressive Disorder
Primary: Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale — -4.34; -3.90 units on a scale — p=0.397
Hypertension
Primary: The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks — 75.8…
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Multiple Myeloma
Primary: Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. — 0.716; 0.344; 0.284; 0.656 proportion of participants